Although genetic alterations in PTC can differ among different ethnicities, the AF of BRAF V600E and TERT mutations may be similar. The AF of BRAF V600E has the potential to be a novel indicator in predicting PTC invasiveness and prognosis.

8 months ago

Retrospective data • Journal

BRAF (B-raf proto-oncogene) • TERT (Telomerase Reverse Transcriptase)

BRAF V600E • BRAF V600 • TERT mutation • TERT promoter mutation • BRAF V600E + TERT mutation

over1year

Transformation of Poorly Differentiated Papillary Thyroid Carcinoma to Anaplastic Thyroid Carcinoma, An Atypical Course! (ENDO 2023)

Combination dabrafenib and trametinib were started. ATC prognosis is affected by many factors such as metastasis, age, treatment strategies, socioeconomic status and the presence of BRAF V600E and TERT mutations. Diagnosis can be challenging. Our patient presented months after his symptoms started and this is an atypical course of Anaplastic Thyroid Carcinoma as it usually progresses aggressively and rapidly.

over 1 year ago

IO biomarker

BRAF (B-raf proto-oncogene) • TERT (Telomerase Reverse Transcriptase)

BRAF V600E • TERT mutation • BRAF V600E + TERT mutation

Mekinist (trametinib) • Tafinlar (dabrafenib)

over2years

A significance of concomitant BRAFV600E and TERT mutations in Polish patients with papillary thyroid microcarcinoma - a retrospective cohort study based on 430 cases. (PubMed, Thyroid)

Regardless the molecular background of PTMC, the overall response to therapy is excellent, and long-term disease-free survival rates can be achieved by most patients.

over 2 years ago

Retrospective data • Journal

TERT (Telomerase Reverse Transcriptase)

BRAF V600E • BRAF V600 • TERT mutation • BRAF V600E + TERT mutation